Epilepsy News and Research

Latest Epilepsy News and Research

Epilepsy Foundation's week of activities to be held to raise awareness of epilepsy and seizures

More than 5,000 people are expected to participate in the Epilepsy Foundation's week of activities March 23 through 27 to raise public awareness of epilepsy and seizures, increase funding for programs and research, and empower people with epilepsy to become advocates for better health care.

23 Mar 2010

Bakeries across the U.S. join campaign for epilepsy awareness

This week, bakeries across the United States are cooking up purple cupcakes in an effort to increase awareness about epilepsy nationwide. The Great Purple Cupcake Project is an initiative of The Anita Kaufmann Foundation -- an American epilepsy education organization and the US Sponsor of Purple Day for epilepsy awareness.

22 Mar 2010

Americans to join in Purple Day campaign to support epilepsy awareness

Members of the U.S. House and Senate, children in schools across the country, and employees of workplaces nationwide will wear purple to support epilepsy awareness on March 26. Thousands of Americans will also join the campaign by hosting Purple Day activities in their regions.

22 Mar 2010

Young ambassador participates in Epilepsy Foundation’s public health program

Anthony Lippolis of Springfield, OH will travel to Washington, D.C., Tuesday, March 23 through Thursday, March 25, 2010 to meet with congressional leaders and gain their support for epilepsy public health programs and more research toward a cure for epilepsy.

20 Mar 2010

PhRMA President honors Ron and Raychel Bartek for driving awareness of Friedreich's ataxia

Pharmaceutical Research and Manufacturers of America President and CEO Billy Tauzin today honored Ron and Raychel Bartek for their dedicated work driving awareness of Friedreich's ataxia, a debilitating, life-threatening, rare disease.

19 Mar 2010

Study results of Medtronic DBS Therapy for epilepsy published in Epilepsia

Medtronic, Inc. today announced that a landmark publication highlighting results from the pivotal study for Medtronic Deep Brain Stimulation (DBS) Therapy for epilepsy, known as SANTE® (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy), was published online today in the medical journal, Epilepsia. The SANTE study, sponsored by Medtronic, is the largest and most rigorous clinical study of DBS therapy for epilepsy in adults with medically refractory epilepsy with partial-onset seizures.

19 Mar 2010

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

The Epilepsy Therapy Project, a non-profit organization dedicated to accelerating new therapies for people living with epilepsy, today released presentation highlights following its successful 2010 Epilepsy Pipeline Update Conference held in San Francisco. Sponsored by ETP, this conference brings together leading clinical investigators, emerging CNS companies and academic innovators with investors and business development partners to facilitate professional collaboration, funding and partnerships that will accelerate patient access to new treatments.

18 Mar 2010

SANTE study: Deep brain stimulation can reduce seizures

A recent study organized by Stanford University researchers found patients with refractory partial and secondarily generalized seizures had a reduction in seizures after deep brain stimulation. This multi-center clinical trial determined that the benefits of stimulation of the anterior nuclei of thalamus for epilepsy (SANTE) persisted and by 2 years there was a 56% reduction in seizure frequency.

18 Mar 2010

Scientists discover switch mechanism that controls cells' trafficking system

Scientists have identified a mechanism that switches on an extremely important process for the proper functioning and survival of our body's cells. Specifically, the fast-track transportation pathway of 'cargo' to and from the surface of the cell.

18 Mar 2010

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

It is announced today that CNS Network has purchased ALPHADAS®, Logos Technologies Inc’s early phase, e-source data capture system and site automation tools to accelerate and streamline its clinical trials. ALPHADAS is to be implemented in their Orange County Research Center, California, USA.

17 Mar 2010

Pathway Genomics' personal Genetic Health Report now available

Pathway Genomics Inc., a U.S. based genetic testing company, announced the immediate availability of its personal Genetic Health Report. This customized and innovative personal genetic health report contains information on more than 70 health conditions, including pharmacogenetics (prescription medication response), propensity for complex disease, and carrier status (pre-pregnancy health).

17 Mar 2010

Methamphetamine abuse during pregnancy leads to structural abnormalities in brain of children

It has long been known that alcohol exposure is toxic to the developing fetus and can result in lifelong brain, cognitive and behavioral problems. Now, a new report out of UCLA shows that the effects of prenatal methamphetamine exposure - or worse, a combination of methamphetamine and alcohol - may be even more damaging.

17 Mar 2010

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Vertex Pharmaceuticals Incorporated today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010.

17 Mar 2010

Positive results from Phase IIa epilepsy study of ICA-105665

Icagen, Inc. today reported positive results in its Phase IIa epilepsy study of ICA-105665, the Company's novel orally available small molecule KCNQ potassium channel agonist.

16 Mar 2010

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company’s approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix’s patent application, “Methods and Compositions for the Treatment of Neurological Disease,” which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain’s temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).

15 Mar 2010

FDA Neurological Devices Panel recommends approval of DBS Therapy for epilepsy

The U.S. Food and Drug Administration Neurological Devices Panel today voted seven to five to recommend approval with conditions of Deep Brain Stimulation (DBS) Therapy for Epilepsy from Medtronic, Inc. as adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy.

15 Mar 2010

Landmark clinical trial examines effective treatment options for childhood epilepsy

One of the oldest available anti-seizure medications, ethosuximide, is the most effective treatment for childhood absence epilepsy, according to initial outcomes published in this week's New England Journal of Medicine.

15 Mar 2010

New MMMCC center improves patients’ access to medical marijuana

Marijuana is not just for brownies anymore. It has touched the lives of thousands of Michigan residents who are struggling with chronic pain, severe nausea, seizures, spasms or wasting syndrome.

12 Mar 2010

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat- (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

Epilepsy News and Research

Latest Epilepsy News and Research

Epilepsy Foundation's week of activities to be held to raise awareness of epilepsy and seizures

Bakeries across the U.S. join campaign for epilepsy awareness

Americans to join in Purple Day campaign to support epilepsy awareness

Young ambassador participates in Epilepsy Foundation’s public health program

PhRMA President honors Ron and Raychel Bartek for driving awareness of Friedreich's ataxia

Study results of Medtronic DBS Therapy for epilepsy published in Epilepsia

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

SANTE study: Deep brain stimulation can reduce seizures

Scientists discover switch mechanism that controls cells' trafficking system

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

Pathway Genomics' personal Genetic Health Report now available

Methamphetamine abuse during pregnancy leads to structural abnormalities in brain of children

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Positive results from Phase IIa epilepsy study of ICA-105665

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

FDA Neurological Devices Panel recommends approval of DBS Therapy for epilepsy

Landmark clinical trial examines effective treatment options for childhood epilepsy

New MMMCC center improves patients’ access to medical marijuana

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Epilepsy News and Research

Latest Epilepsy News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in